Biodexa Pharmaceuticals (BDRX) Return on Capital Employed (2016 - 2025)

Biodexa Pharmaceuticals (BDRX) reported Return on Capital Employed of 157.97% for Q2 2025, up 23.52% sequentially from 206.54% in Q4 2024.

Biodexa Pharmaceuticals (BDRX) Return on Capital Employed (2016 - 2025) Analysis & Trends

Biodexa Pharmaceuticals (BDRX) has 6 years of Return on Capital Employed data on file, last reported at 157.97% in Q2 2025.

For the quarter ending Q2 2025, Return on Capital Employed changed N/A year-over-year to 157.97%; the trailing twelve-month figure through Jun 2025 stood at 157.97% (changed N/A YoY), and the FY2025 full-year result was 85.14%, up 3811.0% from the prior year.
Return on Capital Employed improved to 157.97% in Q2 2025, from 206.54% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 157.97% in Q2 2025 to a low of 513.99% in Q4 2023.
A 3-year average of 307.11% and a median of 278.23% in 2023 frame the typical range for Return on Capital Employed.
Peak annual rise in Return on Capital Employed reached 30746 bps in 2024, while the deepest fall reached 30746 bps in 2024.
Tracing BDRX's Return on Capital Employed over 3 years: stood at 513.99% in 2023, then jumped by 60 bps to 206.54% in 2024, then gained by 24 bps to 157.97% in 2025.
Business Quant data shows BDRX's Return on Capital Employed at 157.97% in Q2 2025, 206.54% in Q4 2024, and 513.99% in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-31.80%
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-107.40%
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	10.46%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	21.10%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	10.19%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-68.84%
10	Biodexa Pharmaceuticals	17.56 Bn	17.54 Bn	-	-

Download Data